IART on Nasdaq
INTEGRA LIFESCIENCES HOLDINGS CORP
Global medical technology company dedicated to restoring lives1
In its 2026 annual report the company says: “We are the world leader in neurosurgery and one of the top three providers in the U.S. in instruments used in precision, specialty, and general surgical procedures. Our TT segment generates about 30% of our overall revenue and focuses on wound reconstruction and care and private label. We were the first company to receive an FDA claim for regeneration of dermal tissue and are a world leader in regenerative technology.”4 It is headquartered in Princeton, New Jersey.1 Its shares trade on Nasdaq under the symbol IART.1
Price unavailable
Last updated Oct 21, 2026.
Overview
Compare with MERIT MEDICAL SYSTEMS INC, Penumbra or Teleflex, or pick any stock.
- TickerIART on Nasdaq1
- IndustrySurgical & Medical Instruments & Apparatus1
- HeadquartersPrinceton, New Jersey1
- Incorporated inDE2
- Business address1100 Campus Road, Princeton, Nj 085402
- Filer categoryLarge accelerated filer2
See how the biggest companies compare on our leaderboards
Integra LifeSciences Holdings Corporation is a global medical technology company dedicated to restoring lives. We are advancing transformational care through impactful innovation and our portfolio of highly differentiated technologies is trusted by healthcare professionals to deliver transformative care.4 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
-30.2%Operating margin5
-31.6%Net margin5
1.5%Revenue growth, 20255
-49.5%Return on equity5
0.70×Debt to equity5
-$31.1MFree cash flow5
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Business segments
Codman Specialty Surgical brought in 73% of the revenue INTEGRA LIFESCIENCES HOLDINGS CORP broke down this way in fiscal 2025.
Business segments by year
| Business segments | 2023 | 2024 | 2025 |
|---|---|---|---|
| Codman Specialty Surgical | $1.1B | $1.1B | $1.2B |
| Tissue Technologies | $482.6M | $466.9M | $434.7M |
Regions
United States brought in 74% of the revenue INTEGRA LIFESCIENCES HOLDINGS CORP broke down this way in fiscal 2025.
Regions by year
| Regions | 2023 | 2024 | 2025 |
|---|---|---|---|
| United States | $1.1B | $1.2B | $1.2B |
| Asia Pacific | $193.1M | $176.6M | $189.3M |
| Europe | $165.2M | $158.5M | $162.7M |
| Rest of the World | $82.5M | $82.7M | $78.6M |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue49¢$803.6M
- Selling, general and admin43¢$699.7M
- Other costs5¢$84.9M
- Income tax3¢$47.0M
Out of $1.6B in revenue.5 The company lost money this year.
Where each dollar of operating cash went, fiscal 2025
- Capital spending100¢$81.4M
- Share buybacks0¢$221.0K
Out of $50.4M of cash from operations. Spending exceeded cash from operations; the rest came from savings or borrowing.5
Financial statements
Every line of the income statement as filed: the last 3 fiscal years, latest first.5
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Total Revenue, net | $1.6B | $1.6B | $1.5B |
| Cost of goods sold | $803.6M | $728.5M | $656.8M |
| Research and development | $99.0M | $115.4M | $104.2M |
| Selling, general and administrative | $699.7M | $717.0M | $656.6M |
| Intangible asset amortization | $15.0M | $21.3M | $12.4M |
| Goodwill impairment charge | $511.4M | $0 | $0 |
| Total costs and expenses | $2.1B | $1.6B | $1.4B |
| Operating (loss) income | -$493.4M | $28.4M | $111.5M |
| Interest income | $18.5M | $20.0M | $17.2M |
| Interest expense | -$86.3M | -$70.6M | -$51.4M |
| Other (expense) income, net | -$2.4M | $3.9M | $3.7M |
| (Loss) income before income taxes | -$563.5M | -$18.2M | $81.1M |
| (Benefit) provision for income taxes | -$47.0M | -$11.3M | $13.3M |
| Net (loss) income | -$516.5M | -$6.9M | $67.7M |
| Basic (in dollars per share) | -$6.74 | -$0.09 | $0.85 |
| Diluted (in dollars per share) | -$6.74 | -$0.09 | $0.84 |
| Basic (in shares) | 76.7M shares | 77.0M shares | 80.1M shares |
| Diluted (in shares) | 76.7M shares | 77.0M shares | 80.3M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.5
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $235.0M | $246.4M | ||
| Short-term investments | $28.7M | $27.2M | ||
| Trade accounts receivable, net of allowances of $7,230 and $6,917 | $278.8M | $272.4M | ||
| Inventories, net | $492.7M | $429.1M | ||
| Prepaid expenses | $96.1M | $77.0M | ||
| Other current assets | $28.1M | $29.7M | ||
| Total current assets | $1.2B | $1.1B | ||
| Property, plant and equipment, net | $444.3M | $405.7M | ||
| Right of use asset - operating leases | $140.6M | $144.0M | ||
| Intangible assets, net | $1.1B | $1.2B | ||
| Goodwill | $615.2M | $1.1B | $1.1B | |
| Deferred tax assets, net | $69.9M | $34.9M | ||
| Other assets | $37.9M | $66.5M | ||
| Total assets | $3.6B | $4.0B | ||
| Current portion of borrowings under senior credit facility | $38.8M | $33.9M | ||
| Short-term borrowings under securitization facility | $87.8M | $0 | ||
| Current portion of lease liability - operating leases | $14.0M | $14.5M | ||
| Convertible securities | $0 | $573.2M | ||
| Accounts payable, trade | $95.7M | $82.5M | ||
| Contract liabilities | $11.5M | $10.5M | ||
| Income tax payable | $3.7M | $0 | ||
| Accrued compensation | $74.1M | $85.6M | ||
| Accrued expenses and other current liabilities | $130.5M | $121.9M | ||
| Total current liabilities | $456.0M | $922.1M | ||
| Long-term borrowings under senior credit facility | $1.7B | $1.1B | ||
| Long-term borrowings under securitization facility | $0 | $108.1M | ||
| Lease liability - operating leases | $163.1M | $166.9M | ||
| Deferred tax liabilities | $5.7M | $60.8M | ||
| Other liabilities | $204.3M | $146.2M | ||
| Total liabilities | $2.6B | $2.5B | ||
| Preferred Stock; no par value; 15,000 authorized shares; none outstanding | $0 | $0 | ||
| Common stock; $0.01 par value; 240,000 authorized shares; 92,286 and 91,610 issued at December 31, 2025 and 2024, respectively | $923.0K | $916.0K | ||
| Additional paid-in capital | $1.3B | $1.3B | ||
| Treasury stock, at cost; 14,399 and 14,445 shares at December 31, 2025 and 2024, respectively | -$689.2M | -$691.4M | ||
| Accumulated other comprehensive (loss) | -$30.1M | -$27.6M | ||
| Retained earnings | $423.4M | $939.9M | ||
| Total stockholders equity | $1.0B | $1.5B | $1.6B | $1.8B |
| Total liabilities and stockholders equity | $3.6B | $4.0B | ||
| Trade accounts receivable, allowances | $7.2M | $6.9M | ||
| Preferred stock, par value (in dollars per share) | $0.00 | $0.00 | ||
| Preferred stock, authorized shares (in shares) | 15.0M shares | 15.0M shares | ||
| Preferred stock, outstanding (in shares) | 0 shares | 0 shares | ||
| Common stock, par value (in dollars per share) | $0.01 | $0.01 | ||
| Common stock, authorized shares (in shares) | 240.0M shares | 240.0M shares | ||
| Common stock, issued (in shares) | 92.3M shares | 91.6M shares | ||
| Treasury stock outstanding (in shares) | 14.4M shares | 14.4M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $235.0M | $246.4M | ||
| Short-term investments | $28.7M | $27.2M | ||
| Trade accounts receivable, net of allowances of $7,230 and $6,917 | $278.8M | $272.4M | ||
| Inventories, net | $492.7M | $429.1M | ||
| Prepaid expenses | $96.1M | $77.0M | ||
| Other current assets | $28.1M | $29.7M | ||
| Total current assets | $1.2B | $1.1B | ||
| Property, plant and equipment, net | $444.3M | $405.7M | ||
| Right of use asset - operating leases | $140.6M | $144.0M | ||
| Intangible assets, net | $1.1B | $1.2B | ||
| Goodwill | $615.2M | $1.1B | $1.1B | |
| Deferred tax assets, net | $69.9M | $34.9M | ||
| Other assets | $37.9M | $66.5M | ||
| Total assets | $3.6B | $4.0B | ||
| Current portion of borrowings under senior credit facility | $38.8M | $33.9M | ||
| Short-term borrowings under securitization facility | $87.8M | $0 | ||
| Current portion of lease liability - operating leases | $14.0M | $14.5M | ||
| Convertible securities | $0 | $573.2M | ||
| Accounts payable, trade | $95.7M | $82.5M | ||
| Contract liabilities | $11.5M | $10.5M | ||
| Income tax payable | $3.7M | $0 | ||
| Accrued compensation | $74.1M | $85.6M | ||
| Accrued expenses and other current liabilities | $130.5M | $121.9M | ||
| Total current liabilities | $456.0M | $922.1M | ||
| Long-term borrowings under senior credit facility | $1.7B | $1.1B | ||
| Long-term borrowings under securitization facility | $0 | $108.1M | ||
| Lease liability - operating leases | $163.1M | $166.9M | ||
| Deferred tax liabilities | $5.7M | $60.8M | ||
| Other liabilities | $204.3M | $146.2M | ||
| Total liabilities | $2.6B | $2.5B | ||
| Preferred Stock; no par value; 15,000 authorized shares; none outstanding | $0 | $0 | ||
| Common stock; $0.01 par value; 240,000 authorized shares; 92,286 and 91,610 issued at December 31, 2025 and 2024, respectively | $923.0K | $916.0K | ||
| Additional paid-in capital | $1.3B | $1.3B | ||
| Treasury stock, at cost; 14,399 and 14,445 shares at December 31, 2025 and 2024, respectively | -$689.2M | -$691.4M | ||
| Accumulated other comprehensive (loss) | -$30.1M | -$27.6M | ||
| Retained earnings | $423.4M | $939.9M | ||
| Total stockholders equity | $1.0B | $1.5B | $1.6B | $1.8B |
| Total liabilities and stockholders equity | $3.6B | $4.0B | ||
| Trade accounts receivable, allowances | $7.2M | $6.9M | ||
| Preferred stock, par value (in dollars per share) | $0.00 | $0.00 | ||
| Preferred stock, authorized shares (in shares) | 15.0M shares | 15.0M shares | ||
| Preferred stock, outstanding (in shares) | 0 shares | 0 shares | ||
| Common stock, par value (in dollars per share) | $0.01 | $0.01 | ||
| Common stock, authorized shares (in shares) | 240.0M shares | 240.0M shares | ||
| Common stock, issued (in shares) | 92.3M shares | 91.6M shares | ||
| Treasury stock outstanding (in shares) | 14.4M shares | 14.4M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.5
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net (loss) income | -$516.5M | -$6.9M | $67.7M |
| Depreciation and amortization | $151.8M | $140.9M | $123.5M |
| Non-cash impairment charges | $511.4M | $12.2M | $0 |
| Deferred income tax benefit | -$66.3M | -$20.7M | -$11.9M |
| Share-based compensation | $18.6M | $24.4M | $20.1M |
| Amortization of debt issuance costs and expenses associated with debt refinancing | $5.6M | $5.6M | $6.2M |
| Non-cash lease expense | -$987.0K | $835.0K | $2.2M |
| Lease incentive | $1.3M | $8.5M | $0 |
| Loss on disposal of property and equipment and construction in-progress | $490.0K | $1.5M | $777.0K |
| Change in fair value of contingent consideration and others | -$21.3M | -$5.8M | $12.9M |
| Accounts receivable | -$485.0K | $7.4M | $4.6M |
| Inventories | -$46.8M | -$28.1M | -$59.8M |
| Prepaid expenses and other current assets | -$2.8M | -$8.2M | $2.7M |
| Other non-current assets | $3.3M | -$2.8M | -$8.5M |
| Accounts payable, accrued expenses and other current liabilities | $26.7M | -$2.7M | -$20.2M |
| Contract liabilities | $3.4M | $3.5M | $128.0K |
| Other non-current liabilities | -$17.2M | -$93.0K | -$410.0K |
| Net cash provided by operating activities | $50.4M | $129.4M | $140.0M |
| Purchases of property and equipment | -$81.4M | -$104.4M | -$66.9M |
| Purchases of intangible assets | -$14.2M | -$10.0M | $0 |
| Purchases of short-term investments | -$8.5M | -$49.0M | -$32.7M |
| Proceeds from maturities of short-term investments | $7.0M | $54.5M | $0 |
| Cash paid for business acquisitions, net of cash acquired | $0 | -$277.8M | $0 |
| Net (payment) proceeds on swaps designated as net investment hedges | -$10.9M | -$4.1M | $5.4M |
| Net cash used in investing activities | -$108.1M | -$390.8M | -$94.2M |
| Proceeds from borrowings of long-term indebtedness | $720.7M | $486.5M | $165.1M |
| Payments on debt | -$94.9M | -$187.1M | -$110.6M |
| Repayments of convertible debt | -$575.0M | $0 | $0 |
| Payment of debt issuance costs | -$4.1M | $0 | -$7.9M |
| Purchase of treasury stock | -$221.0K | -$52.5M | -$275.0M |
| Payments for contingent considerations | -$16.5M | -$11.9M | $0 |
| Proceeds from exercise of stock options and employee stock purchase plan | $957.0K | $6.4M | $4.3M |
| Cash taxes paid in net equity settlement | -$2.7M | -$3.5M | -$5.9M |
| Net cash provided by (used in) financing activities | $28.3M | $237.9M | -$229.9M |
| Effect of exchange rate changes on cash and cash equivalents | $18.0M | -$6.5M | $3.9M |
| Net decrease in cash and cash equivalents | -$11.3M | -$30.0M | -$180.3M |
No quarter-by-quarter statement was filed.
Compare INTEGRA LIFESCIENCES HOLDINGS CORP with another company
Corporate structure
INTEGRA LIFESCIENCES HOLDINGS CORP sits at the top of its group. 90 entities, 25 countries on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of INTEGRA LIFESCIENCES HOLDINGS CORP
- PARADIGM CAPITAL MANAGEMENT INC/NY Filed SCHEDULE 13G/A on INTEGRA LIFESCIENCES HOLDINGS CORP, latest Aug 13, 2026 (2 filings since May 15, 2026)
- VANGUARD PORTFOLIO MANAGEMENT LLC Filed SCHEDULE 13G on INTEGRA LIFESCIENCES HOLDINGS CORP, latest Jul 31, 2026
- VANGUARD GROUP INC Filed SCHEDULE 13G/A on INTEGRA LIFESCIENCES HOLDINGS CORP, latest Mar 27, 2026 (5 filings since Feb 10, 2022)
- FULLER & THALER ASSET MANAGEMENT, INC. Filed SCHEDULE 13G/A on INTEGRA LIFESCIENCES HOLDINGS CORP, latest Feb 17, 2026 (2 filings since Nov 12, 2024)
- Invesco Filed SCHEDULE 13G/A on INTEGRA LIFESCIENCES HOLDINGS CORP, latest Nov 6, 2025 (2 filings since May 9, 2025)
- Morgan Stanley Filed SCHEDULE 13G/A on INTEGRA LIFESCIENCES HOLDINGS CORP, latest Aug 5, 2025 (4 filings since Feb 11, 2022)
- BlackRock Filed SCHEDULE 13G/A on INTEGRA LIFESCIENCES HOLDINGS CORP, latest Jul 17, 2025 (5 filings since Feb 1, 2022)
- Rubric Capital Management LP Filed SCHEDULE 13G/A on INTEGRA LIFESCIENCES HOLDINGS CORP, latest Jul 9, 2025 (2 filings since May 14, 2025)
- Capital Research Global Investors Filed SC 13G/A on INTEGRA LIFESCIENCES HOLDINGS CORP, latest Nov 12, 2024 (4 filings since Feb 11, 2022)
- Champlain Investment Partners, LLC Filed SC 13G/A on INTEGRA LIFESCIENCES HOLDINGS CORP, latest Feb 13, 2024 (3 filings since Feb 11, 2022)
- Wellington Management Company Filed SC 13G/A on INTEGRA LIFESCIENCES HOLDINGS CORP, latest Feb 9, 2024 (4 filings since Feb 4, 2022)
- Tru St Partnership, L.P. Filed SC 13G/A on INTEGRA LIFESCIENCES HOLDINGS CORP, latest Feb 14, 2023 (2 filings since Feb 14, 2022)
- INTEGRA LIFESCIENCES HOLDINGS CORP Princeton, New Jersey
- Acclarent, Inc. Subsidiary · Delaware, United States
- ACell, Inc. Subsidiary · Delaware, United States
- Arkis Biosciences Inc. Subsidiary · Delaware, United States
- Ascension Orthopedics Limited Subsidiary · United Kingdom
- BIMECO, Inc. Subsidiary · Florida, United States
- BioD, LLC Subsidiary · Delaware, United States
- BioDlogics, LLC Subsidiary · Delaware, United States
- BioRecovery, LLC Subsidiary · Delaware, United States
- CardioDyne, Inc. Subsidiary · Massachusetts, United States
- Cathtec Incorporated Subsidiary · Massachusetts, United States
- Caveangle Limited Subsidiary · United Kingdom
- Confluent Surgical, Inc. Subsidiary · Delaware, United States
- Derma First Aid Products, Inc. Subsidiary · Pennsylvania, United States
- Derma Sciences Europe Limited Subsidiary · United Kingdom
- Derma Sciences, Inc. Subsidiary · Delaware, United States
- EndoSolutions, Inc. Subsidiary · Delaware, United States
- Fiber Imaging Technologies, Inc. Subsidiary · Massachusetts, United States
- GMS, Gesellschaft für medizinische Sondentechnik mbH Subsidiary · Germany
- ILS Financing (Ireland) Limited Subsidiary · Ireland
- ILS Financing Corporation Subsidiary · Delaware, United States
- ILS Services Switzerland Ltd. Subsidiary · Switzerland
- ILS Surgical Investments, LLC Subsidiary · Delaware, United States
- INS Sweden AB Subsidiary · Sweden
- Integra Burlington MA, Inc. (formerly known as Integra Radionics, Inc.) Subsidiary · Delaware, United States
- Integra Canada ULC (formerly known as Canada Microsurgical ULC) Subsidiary · Canada
- and 64 more
Built from subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What INTEGRA LIFESCIENCES HOLDINGS CORP reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Property and equipment, before depreciation | $888.3M5 Dec 31, 2025 | $802.6M5 Dec 31, 2024 | +10.7% |
| Accumulated depreciation | $444.0M5 Dec 31, 2025 | $396.9M5 Dec 31, 2024 | +11.8% |
| Property and equipment, net | $444.3M5 Dec 31, 2025 | $405.7M5 Dec 31, 2024 | +9.5% |
| Operating-lease assets (leased space) | $140.6M5 Dec 31, 2025 | $144.0M5 Dec 31, 2024 | −2.4% |
Investments
| Item | Latest | A year before | Change |
|---|---|---|---|
| Cash and cash equivalents | $235.0M5 Dec 31, 2025 | $246.4M5 Dec 31, 2024 | −4.6% |
| Marketable securities, current | $28.7M5 Dec 31, 2025 | $27.2M5 Dec 31, 2024 | +5.5% |
Intangibles and goodwill
| Item | Latest | A year before | Change |
|---|---|---|---|
| Goodwill | $615.2M5 Dec 31, 2025 | $1.1B5 Dec 31, 2024 | −43.9% |
| Intangible assets, net (excluding goodwill) | $1.1B5 Dec 31, 2025 | $1.2B5 Dec 31, 2024 | −6.0% |
| Accumulated amortization | $858.1M5 Dec 31, 2025 | $732.2M5 Dec 31, 2024 | +17.2% |
Inventory
| Item | Latest | A year before | Change |
|---|---|---|---|
| Inventory, total | $492.7M5 Dec 31, 2025 | $429.1M5 Dec 31, 2024 | +14.8% |
| Raw materials | $130.8M5 Dec 31, 2025 | $125.9M5 Dec 31, 2024 | +3.8% |
| Work in process | $99.3M5 Dec 31, 2025 | $79.4M5 Dec 31, 2024 | +25.1% |
| Finished goods | $262.6M5 Dec 31, 2025 | $223.7M5 Dec 31, 2024 | +17.4% |
Properties, in its own words
As of December 31, 2025, we lease approximately 166,991 square feet of space in Princeton, NJ, where we house our principal headquarters, sales operations, and support functions. This lease expires in 2035.
We own facilities in Saint Aubin Le Monial, France, Rietheim-Weilheim, Germany, Plainsboro, New Jersey and Cincinnati, Ohio and we lease all of our other facilities.
The rest of Item 2
We have key manufacturing and research facilities located in California, Maryland, Massachusetts, New Jersey, Ohio, Puerto Rico, Tennessee, Utah, France, Germany, Ireland, Israel, and Switzerland. Our instrument procurement operations are located in Germany.
Our primary distribution centers are located in Kentucky, Nevada, Australia, Belgium, Canada, Italy, Japan, and China. In addition, we lease several smaller facilities to support additional administrative, assembly, and distribution operations.
In addition to the Company’s primary operations, we have dedicated repair facilities located in multiple countries around the world.
Our manufacturing facilities are registered with the FDA. Our facilities are subject to FDA inspection to ensure compliance with Quality System regulations. For further information regarding the status of FDA inspections, see the “Item 1. Business –Government Regulation and Compliance” and “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations – FDA Matters” in this Annual Report on Form 10-K.
Item 2 of the 10-K filed Feb 26, 2026.4
Leadership
Who has led INTEGRA LIFESCIENCES HOLDINGS CORP, and when. Pick a name to see everywhere that person has worked.
Chair
Chief financial officer
Chief operating officer
2010201520202025
- Chief executive officerMojdeh Poul Jan 7, 2025 to now14
- Chief executive officerWitte Jan De Dec 10, 2021 to Nov 4, 202415
- Chief executive officerPeter Arduini Jan 4, 2012 to Sep 7, 202116
- Chief executive officerStuart Essig Jan 5, 2006 to Jan 4, 201217
- ChairStuart Essig Feb 23, 2012 to now18
- PresidentMojdeh Poul Jan 7, 2025 to now14
- PresidentWitte Jan De Dec 10, 2021 to Nov 4, 202415
- PresidentPeter Arduini Nov 3, 2010 to Sep 7, 202119
- PresidentStuart Essig Jan 5, 2006 to Nov 3, 201017
- Chief financial officerLea Daniels Knight Jul 6, 2023 to now20
- Chief financial officerCarrie L. Anderson Jul 2, 2019 to Jul 5, 202221
- Chief financial officerGlenn Coleman May 5, 2014 to Mar 15, 201922
- Chief financial officerJohn B. Henneman Iii. Dec 7, 2007 to Mar 26, 201423
- Chief financial officerMaureen B. Bellantoni Jan 20, 2006 to Apr 4, 200724
- Chief operating officerGlenn Coleman Jul 2, 2019 to Jul 5, 202225
- Chief operating officerPeter Arduini Nov 3, 2010 to Nov 3, 201019
- Chief operating officerGerard S. Carlozzi Jan 26, 2006 to Apr 5, 201026
Board members and other officers (40)
- EVP & CHROChantal Veillon-Berteloot Sep 5, 2023 to now27
- Exec VP & PRES, InternationalHarvinder Singh Oct 12, 2022 to now28
- Executive VP & President, CSSMichael J. McBreen Jun 12, 2020 to now29
- Principal Accounting OfficerJeffrey Mosebrook Oct 26, 2017 to now30
- Chief Human Resources OfficerLisa Evoli Jan 14, 2016 to Mar 14, 202331
- CORPVP,CHIEFSCIENTIFIC OFFICERKenneth Burhop Mar 5, 2014 to Feb 18, 202032
- CVP,PRES-ORTHO & TISSUE TECHMark A. Augusti Apr 9, 2014 to Oct 11, 201633
- Corp VP, Pres.Gbl Spine &OrthoBrian Larkin Dec 10, 2012 to Apr 6, 201534
- Corp VP, Pres.- Surgl InstrmntDaniel L. Reuvers Dec 10, 2012 to May 13, 202035
- Corp VP, Global Ops & Supp ChnJohn Mooradian Dec 10, 2012 to Feb 18, 202036
- Corp VP,Global Qlty AssuranceJoseph Vinhais Dec 10, 2012 to Sep 13, 201937
- Corp VP, Chief HR OfficerPadma Thiruvengadam Dec 10, 2012 to Apr 6, 201538
- Corp VP, Gen Counsel & SecRichard D. Gorelick Dec 10, 2012 to Mar 27, 201839
- Senior VP, Global MarketingDeborah A. Leonetti Jan 5, 2006 to May 12, 201540
- Senior VP, OperationsDon R. Nociolo Jan 5, 2006 to Mar 16, 200641
- Sr VP, Regulatory, Quality,Judith Ogrady Jan 5, 2006 to Feb 18, 202042
- Sr. VP, Global SalesRobert D. Paltridge Jan 5, 2006 to Jul 2, 201443
- Exec VP, CAO, & SecretaryJohn B. Henneman Iii. Jan 10, 2006 to Aug 26, 201444
- Sr. VP, Finance, TreasurerDavid B. Holtz Feb 7, 2006 to Jan 3, 200745
- VP and Corporate ControllerJerry E. Corbin Nov 16, 2006 to Jul 2, 201446
- Board memberMojdeh Poul Jan 7, 2025 to now14
- Board memberJeffrey A. Graves Dec 13, 2023 to now47
- Board memberRenee Wonlai Lo Jul 27, 2022 to now48
- Board memberShaundra Clay Apr 19, 2021 to now49
- Board memberWitte Jan De Dec 10, 2021 to Nov 4, 202415
- Board memberRhonda Germany Ballintyn Jan 10, 2019 to May 17, 202150
- Board memberLloyd Howell Jr. Mar 19, 2013 to May 15, 202051
- Board memberBarbara B. Hill May 22, 2013 to now52
- Board memberDonald E. Morel Jr. Aug 27, 2013 to May 17, 202253
- Board memberPeter Arduini Jan 4, 2012 to Sep 7, 202116
- Board memberThomas Baltimore Mar 7, 2007 to May 21, 201254
- Board memberStuart Essig Jan 5, 2006 to now17
- Board memberKeith Bradley Feb 24, 2006 to now55
- Board memberJames M. Sullivan Apr 3, 2006 to May 21, 201856
- Board memberRichard E. Caruso May 1, 2006 to May 26, 201657
- Board memberAnne Vanlent May 18, 2006 to May 21, 201258
- Board memberChristian S. Schade May 18, 2006 to now59
- Board memberNeal Moszkowski Aug 10, 2006 to May 24, 201360
- General counselMichael David Hutchinson Feb 4, 2026 to now61
- General counselLesha R. Shinn Sep 28, 2026 to now62
Subsidiaries and ownership
Subsidiaries (Exhibit 21)
- ACell, Inc. Delaware3
- Acclarent, Inc. Delaware3
- Arkis Biosciences Inc. Delaware3
- Ascension Orthopedics Limited United Kingdom3
- BIMECO, Inc. Florida3
- BioD, LLC Delaware3
- BioDlogics, LLC Delaware3
- BioRecovery, LLC Delaware3
- CardioDyne, Inc. Massachusetts3
- Cathtec Incorporated Massachusetts3
- Caveangle Limited United Kingdom3
- Confluent Surgical, Inc. Delaware3
- Derma First Aid Products, Inc. Pennsylvania3
- Derma Sciences Europe Limited United Kingdom3
- Derma Sciences, Inc. Delaware3
- EndoSolutions, Inc. Delaware3
- Fiber Imaging Technologies, Inc. Massachusetts3
- GMS, Gesellschaft für medizinische Sondentechnik mbH Germany3
- ILS Financing (Ireland) Limited Ireland3
- ILS Financing Corporation Delaware3
- ILS Services Switzerland Ltd. Switzerland3
- ILS Surgical Investments, LLC Delaware3
- INS Sweden AB Sweden3
- Integra Burlington MA, Inc. (formerly known as Integra Radionics, Inc.) Delaware3
All 90 listed subsidiaries
- Integra CI, Inc. Cayman Islands3
- Integra Canada ULC (formerly known as Canada Microsurgical ULC) Canada3
- Integra Euro Holdings, Inc. Delaware3
- Integra France Holdings SAS France3
- Integra German Holdings GmbH Germany3
- Integra GmbH Germany3
- Integra Japan K.K. Japan3
- Integra LS (Benelux) NV Belgium3
- Integra LS Mexico, S. DE R. L. DE C.V. Mexico3
- Integra LifeSciences (Canada) Holdings, Inc. Delaware3
- Integra LifeSciences (Ireland) Limited Ireland3
- Integra LifeSciences (Shanghai) Co., Ltd. China3
- Integra LifeSciences (Suzhou) Co., Ltd. China3
- Integra LifeSciences (Thailand) Limited Thailand3
- Integra LifeSciences Austria GmbH Austria3
- Integra LifeSciences Brazil Ltda. Brazil3
- Integra LifeSciences Corporation Delaware3
- Integra LifeSciences Enterprises, LLLP Delaware3
- Integra LifeSciences Israel Ltd. Israel3
- Integra LifeSciences Italy S.r.l. Italy3
- Integra LifeSciences Production Corporation Delaware3
- Integra LifeSciences Sales LLC (f/k/a Integra Healthcare Products LLC) Delaware3
- Integra LifeSciences Services (France) SAS France3
- Integra LifeSciences Shared Services (Ireland) Limited Ireland3
- Integra LifeSciences Singapore Pte. Ltd. Singapore3
- Integra LifeSciences Spain, S.L. Spain3
- Integra LifeSciences Switzerland Sárl Switzerland3
- Integra LifeSciences Taiwan Company Limited Taiwan3
- Integra Luxtec, Inc. Massachusetts3
- Integra ME GmbH Germany3
- Integra Medical Devices India Private Limited India3
- Integra MicroFrance SAS France3
- Integra NeuroSciences (International), Inc. Delaware3
- Integra NeuroSciences Holdings (UK) Limited United Kingdom3
- Integra NeuroSciences Holdings B.V. Netherlands3
- Integra NeuroSciences Implants (France) SAS France3
- Integra NeuroSciences Limited United Kingdom3
- Integra Neurosciences Pty Ltd. (AUS) Australia3
- Integra Neurosciences Pty Ltd. (NZ) New Zealand3
- Integra Receivables LLC Delaware3
- Integra Sales, Inc. Delaware3
- Integra Selector LLC Delaware3
- Integra Switzerland Holdings Sárl Switzerland3
- Integra York PA, Inc. (formerly known as Miltex, Inc.) Delaware3
- IsoTis NV Netherlands3
- IsoTis T.E. Facility B.V. Netherlands3
- J. Jamner Surgical Instruments, Inc. Delaware3
- Jarit GmbH Germany3
- LXU Healthcare, Inc. - Medical Specialty Products Delaware3
- MedEfficiency, Inc. Delaware3
- Minnesota Scientific, Inc. Minnesota3
- Newdeal SAS France3
- Newdeal, Inc. Texas3
- Precise Dental Holding Corp. New Jersey3
- Precise Dental Internacional, S.A. de C.V. Mexico3
- Precise Dental Products, Ltd. California3
- Precision Dental International, Inc. California3
- Rebound Therapeutics Corporation Delaware3
- Spembly Cryosurgery Limited United Kingdom3
- Spembly Medical Limited United Kingdom3
- Surgical Innovation Associates, Inc. Delaware3
- TEI Biosciences (UK) Limited United Kingdom3
- TEI Biosciences Inc. Delaware3
- TEI Medical Inc. Delaware3
- TGX Medical Systems, LLC Delaware3
- Tarsus Medical Inc. Delaware3
The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.
Former names
- INTEGRA LIFESCIENCES CORPNov 14, 1996 to Mar 31, 19992
Timeline
- Oct 9, 20268-K Regulation FD disclosure63
- Oct 2, 20268-K Results of operations; Regulation FD disclosure64
- Sep 8, 20268-K Regulation FD disclosure65
- Jul 29, 20268-K Results of operations66
- May 8, 20268-K Executive or director change; Shareholder vote67
- May 5, 20268-K Results of operations68
- May 5, 20268-K Executive or director change69
- Apr 15, 20268-K Entered a material agreement70
- Feb 26, 20268-K Results of operations71
- Dec 12, 20258-K Executive or director change72
- Oct 30, 20258-K Results of operations73
- Jul 31, 20258-K Results of operations74
- Jan 7, 2025New chief executive Mojdeh Poul becomes CEO14
- Dec 10, 2021New chief executive Witte Jan De becomes CEO15
- Jan 4, 2012New chief executive Peter Arduini becomes CEO16
- Jan 5, 2006New chief executive Stuart Essig becomes CEO17
Calendar
Coming up
- Oct 21, 2026 · Before the openReports results for the quarter ending Sep/2026 A year earlier it reported $0.54 a share, on Oct 30, 2025.75
When it reported results
- Oct 2, 2026Reported quarterly or annual results64
- Jul 29, 2026Reported quarterly or annual results66
- May 5, 2026Reported quarterly or annual results68
- Feb 26, 2026Reported quarterly or annual results71
- Oct 30, 2025Reported quarterly or annual results73
- Jul 31, 2025Reported quarterly or annual results74
- May 5, 2025Reported quarterly or annual results76
- Feb 25, 2025Reported quarterly or annual results77
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
Filings
320 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 60 major events, 180 insider forms, 37 large holders, 23 other. The latest 20:
- Oct 13, 20263 EDGAR
- Oct 9, 20268-K EDGAR
- Oct 2, 20268-K EDGAR
- Sep 28, 20263 EDGAR
- Sep 8, 20268-K EDGAR
- Sep 4, 20264 EDGAR
- Aug 13, 2026SCHEDULE 13G/A EDGAR
- Jul 31, 2026SCHEDULE 13G EDGAR
- Jul 29, 202610-Q EDGAR
- Jul 29, 20268-K EDGAR
- Jul 6, 20264 EDGAR
- Jul 6, 20264 EDGAR
- Jul 6, 20264 EDGAR
- Jul 6, 20264 EDGAR
- Jun 3, 20264 EDGAR
- Jun 3, 20264 EDGAR
- May 29, 2026SD EDGAR
- May 15, 2026SCHEDULE 13G EDGAR
- May 11, 20264 EDGAR
- May 11, 20264 EDGAR
The 320 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
29 open-market trades by officers, directors and large owners since October 2021: 5 buys and 24 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Nov 5, 2025 | GRAVES JEFFREY ADirector | Buy | 9,000 | $11.35 | $102.2K | Form 4 |
| Dec 3, 2024 | Schwartz EricEVP, Chief Legal Officer & Sec | Sale | 4,070 | $24.60 | $100.1K | Form 4 |
| Dec 2, 2024 | McBreen Michael J.EVP & Chief Commercial Officer | Sale | 1,700 | $24.16 | $41.1K | Form 4 |
| Aug 19, 2024 | Mosebrook JeffreySVP, Fin & Princ Acct Officer | Sale | 1,191 | $21.58 | $25.7K | Form 4 |
| May 23, 2024 | ESSIG STUARTPresident and CEO | Buy | 52,641 | $28.49 | $1.5M | Form 4 |
| May 21, 2024 | HILL BARBARA BDirector | Buy | 36,350 | $27.40 | $996.0K | Form 4 |
| Mar 6, 2024 | DAVIS ROBERT T. JR.EVP & President, TR&DT | Sale | 8,348 | $36.59 | $305.5K | Form 4 |
| Aug 9, 2023 | Mosebrook JeffreySVP, Fin & Princ Acct Officer | Sale | 1,177 | $44.46 | $52.3K | Form 4 |
| Jun 1, 2023 | Schwartz EricEVP, Chief Legal Officer & Sec | Buy | 2,640 | $37.89 | $100.0K | Form 4 |
| Jun 1, 2023 | De Witte JanPresident & CEO | Buy | 7,792 | $38.50 | $300.0K | Form 4 |
| Mar 7, 2023 | McBreen Michael J.EVP & Chief Commercial Officer | Sale | 1,843 | $54.29 | $100.1K | Form 4 |
| Mar 1, 2023 | DAVIS ROBERT T. JR.EVP & President, TR&DT | Sale | 1,566 | $55.21 | $86.5K | Form 4 |
| Feb 27, 2023 | Evoli LisaEVP & CHRO | Sale | 3,767 | $57.00 | $214.7K | Form 4 |
| Dec 8, 2022 | Mosebrook JeffreySVP, Fin & Princ Acct Officer | Sale | 279 | $56.22 | $15.7K | Form 4 |
| Aug 10, 2022 | Evoli LisaEVP & CHRO | Sale | 1,165 | $55.81 | $65.0K | Form 4 |
| Aug 5, 2022 | Murphy Raymond G.Director | Sale | 8,000 | $55.78 | $446.2K | Form 4 |
| Aug 2, 2022 | Mosebrook JeffreySVP, Fin & Princ Acct Officer | Sale | 437 | $56.78 | $24.8K | Form 4 |
| Jun 15, 2022 | Evoli LisaEVP & CHRO | Sale | 900 | $55.93 | $50.3K | Form 4 |
| May 24, 2022 | Evoli LisaEVP & CHRO | Sale | 250 | $59.85 | $15.0K | Form 4 |
| Apr 4, 2022 | Coleman GlennExecutive Vice President & COO | Sale | 6,268 | $66.04 | $413.9K | Form 4 |
All 29 trades can be filtered by person here when JavaScript is on.
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- PARADIGM CAPITAL MANAGEMENT INC/NYSCHEDULE 13G/A, 2 filings May 15, 2026 to Aug 13, 202678
- VANGUARD PORTFOLIO MANAGEMENT LLCSCHEDULE 13G, 1 filing Jul 31, 202679
- VANGUARD GROUP INCSCHEDULE 13G/A, 5 filings Feb 10, 2022 to Mar 27, 202680
- FULLER & THALER ASSET MANAGEMENT, INC.SCHEDULE 13G/A, 2 filings Nov 12, 2024 to Feb 17, 202681
- InvescoSCHEDULE 13G/A, 2 filings May 9, 2025 to Nov 6, 202582
- Morgan StanleySCHEDULE 13G/A, 4 filings Feb 11, 2022 to Aug 5, 202583
- BlackRockSCHEDULE 13G/A, 5 filings Feb 1, 2022 to Jul 17, 202584
- Rubric Capital Management LPSCHEDULE 13G/A, 2 filings May 14, 2025 to Jul 9, 202585
- Capital Research Global InvestorsSC 13G/A, 4 filings Feb 11, 2022 to Nov 12, 202486
- Champlain Investment Partners, LLCSC 13G/A, 3 filings Feb 11, 2022 to Feb 13, 202487
- Wellington Management CompanySC 13G/A, 4 filings Feb 4, 2022 to Feb 9, 202488
- Tru St Partnership, L.P.SC 13G/A, 2 filings Feb 14, 2022 to Feb 14, 202389
- Janus Henderson Group Ltd.SC 13G/A, 1 filing Feb 10, 202290
Executive pay
What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.
| Year | Executive | Age | Salary | Total pay |
|---|---|---|---|---|
| 2025 | Mojdeh Poul | 63 | $1.0M | $9.4M91 |
| 2025 | Lea Knight | 54 | $638.6K | $2.9M91 |
| 2025 | Michael J. McBreen | 60 | $643.8K | $2.7M91 |
| 2025 | Robert T. DavisJr | 67 | $583.4K | $1.9M91 |
| 2025 | Harvinder Singh | 58 | $564.0K | $1.6M91 |
| 2025 | Jan De Witte | $42.3K | $282.7K91 | |
| 2024 | Former President and Chief | $969.0K | $7.5M91 | |
| 2024 | Executive VicePresident and | $616.7K | $3.1M91 | |
| 2023 | Executive Officer and Director | $875.5K | $6.4M91 | |
| 2023 | Chief Financial Officer | $295.4K | $1.7M91 | |
| 2023 | PresidentTissue Technologies | $516.0K | $1.4M91 |
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| BlackRock, Inc. | 10,684,103 | $191.9M | 0.0% | +364,934 |
| Rubric Capital Management LP | 7,753,934 | $139.3M | 1.3% | No change |
| Invesco Ltd. | 3,749,367 | $67.3M | 0.0% | +263,764 |
| Vanguard Portfolio Management LLC | 3,743,093 | $67.2M | 0.0% | +56,456 |
| Morgan Stanley | 3,593,079 | $64.5M | 0.0% | +8,924 |
| Paradigm Capital Management Inc/ny | 3,439,098 | $61.8M | 1.7% | −573,600 |
| Fuller & Thaler Asset Management, Inc. | 3,436,006 | $61.7M | 0.2% | −93,398 |
| State Street Corp | 2,946,862 | $52.9M | 0.0% | +60,306 |
| Vanguard Capital Management LLC | 2,946,173 | $52.9M | 0.0% | +55,349 |
| Neuberger Berman Group LLC | 2,364,777 | $42.6M | 0.0% | +249,522 |
| Dimensional Fund Advisors LP | 2,216,653 | $39.8M | 0.0% | −558,335 |
| Geode Capital Management, LLC | 1,791,635 | $32.2M | 0.0% | +134,650 |
| Goldman Sachs Group Inc | 1,473,719 | $26.5M | 0.0% | −403,031 |
| Wellington Management Group Llp | 1,461,104 | $26.2M | 0.0% | +160,814 |
| Millennium Management LLC | 1,439,747 | $25.9M | 0.0% | +816,894 |
| Charles Schwab Investment Management Inc | 1,401,476 | $25.2M | 0.0% | −210,669 |
| Bank Of America Corp /de/ | 1,329,251 | $23.9M | 0.0% | −85,258 |
| Systematic Financial Management LP | 1,023,243 | $18.4M | 0.4% | −36,043 |
| Allianz Asset Management GmbH | 1,005,203 | $18.1M | 0.0% | +115,599 |
| Glenmede Trust Co Na | 948,142 | $17.0M | 0.1% | −36,544 |
| Northern Trust Corp | 828,532 | $14.9M | 0.0% | +63,259 |
| Balyasny Asset Management L.P. | 640,666 | $11.5M | 0.0% | −53,410 |
| Quantinno Capital Management LP | 609,132 | $10.9M | 0.0% | +149,703 |
| Invenomic Capital Management LP | 579,036 | $10.4M | 0.6% | −432,279 |
| Integral Health Asset Management, LLC | 550,000 | $9.9M | 0.4% | New |
13F reports cover disclosed long positions in U.S. stocks only.
Members of Congress who traded it
9 trades disclosed by members of Congress. “Vs S&P since” is the stock’s change since the trade minus the S&P 500’s.
| Date | Member | Trade | Amount | Vs S&P since | Filing |
|---|---|---|---|---|---|
| Jun 18, 2024 | Josh GottheimerDemocratic, House | Partial sale | $1,001 - $15,000 | +94.1% | Report |
| Apr 5, 2024 | Josh GottheimerDemocratic, House | Partial sale | $1,001 - $15,000 | +109.1% | Report |
| Oct 16, 2023 | Josh GottheimerDemocratic, House | Buy | $1,001 - $15,000 | −141.7% | Report |
| Sep 15, 2023 | Josh GottheimerDemocratic, House | Partial sale | $1,001 - $15,000 | +139.9% | Report |
| Jun 13, 2023 | Josh GottheimerDemocratic, House | Partial sale | $1,001 - $15,000 | +144.0% | Report |
| Oct 16, 2020 | Josh GottheimerDemocratic, House | Buy | $1,001 - $15,000 | −194.3% | Report |
| Sep 15, 2020 | Josh GottheimerDemocratic, House | Partial sale | $1,001 - $15,000 | +197.2% | Report |
| Feb 3, 2020 | Josh GottheimerDemocratic, House | Buy | $1,001 - $15,000 | −213.7% | Report |
| Jan 9, 2019 | Donna Shalala, House | Sale | $1,001 - $15,000 | +269.8% | Report |
Members report amounts as ranges, not exact figures. Returns are price-only (no dividends).
SEC filer profile
How INTEGRA LIFESCIENCES HOLDINGS CORP is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARINTEGRA LIFESCIENCES HOLDINGS CORP1
- CIK0000917520
- Employer ID (EIN)51-03178494
- Filer statusLarge accelerated filer not an emerging growth company; not a smaller reporting company; not a shell company4
- Incorporated inDelaware4
- Fiscal year endsDecember 311
- Industry code (SIC)3841 Surgical & Medical Instruments & Apparatus1
- SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance1
- Business address1100 Campus Road, Princeton, NJ 085401
- Phone60927505001
- Shares outstanding77,772,506 as of Jul 28, 202612
- Public float$925.1M as of Jun 30, 20254
- AuditorPricewaterhouseCoopers LLP, Florham Park, New Jersey PCAOB ID 238; it also attests to the company’s internal control over financial reporting4
- On EDGAR sinceFeb 14, 19961
- Filings2,112 in all: 4 (1,145), 8-K (401), SC 13G/A (115), 10-Q (91), 3 (43), 4/A (38), DEF 14A (31), 10-K (30)1
All 46 form types
SC 13G (25), SC 13D/A (19), 5 (18), S-8 (17), 8-K/A (16), SD (13), ARS (12), UPLOAD (9), S-3ASR (7), SCHEDULE 13G/A (7), CORRESP (6), SC 13D (6), PRE 14A (5), S-3/A (5), 424B7 (4), SC TO-I/A (4), SCHEDULE 13G (4), 144 (3), 424B2 (3), 424B5 (3), DEFA14A (3), NT 10-K (3), POS AM (3), 10-K/A (2), 10-Q/A (2), AW (2), CT ORDER (2), NT 10-Q (2), S-3 (2), SC TO-C (2), T-3 (2), 424B4 (1), DEF 14C (1), POS462B (1), PRE 14C (1), RW (1), SC TO-I (1), T-3/A (1)
- Latest filingsAnnual report (10-K) Feb 26, 2026
Quarterly report (10-Q) Jul 29, 2026
Proxy statement (DEF 14A) Apr 6, 2026
Latest 8-K (8-K) Oct 9, 2026
Securities registered for trading
| Class | Symbol | Exchange |
|---|---|---|
| Common Stock, Par Value $.01 Per Share | IART | Nasdaq Global Select Market |
From the cover page of the 10-K filed Feb 26, 2026 (Section 12(b) of the Exchange Act).4
Risk factors and legal proceedings
The risks INTEGRA LIFESCIENCES HOLDINGS CORP names in Item 1A of its 10-K filed Feb 26, 2026: 31 risks under these headings, as written.4
- The continuing worldwide macroeconomic and geopolitical uncertainty may adversely affect our business and prospects.
- RISKS RELATING TO OUR BUSINESS
- Our operating results may fluctuate.
- The industry and market segments in which we operate are highly competitive, and we may be unable to compete effectively with other companies.
- Changes in the healthcare industry may require us to decrease the selling price for our products, may reduce the size of the market for our products, or may eliminate a market, any of which could have a negative impact on our financial performance.
- We cannot guarantee that any of our acquisitions, investments or alliances will be successful.
- Our global business exposes us to certain operational, compliance and economic risks.
- The current tensions in international trade and rising international political tensions and uncertainties may materially adversely affect our business, financial condition, and results of operations.
- Exchange rate fluctuations and foreign currency hedges could adversely affect our financial results.
- Our future financial results could be adversely affected by impairments or other charges.
- We rely on independent suppliers and third-party providers in our supply chain for raw materials, packaging materials and components, sterilization services, and some finished goods; we could experience inventory shortages if any of these suppliers encounter a manufacturing or distribution disruption.
- We may experience difficulties, delays, performance impact or unexpected costs from consolidation of facilities and transfer of manufacturing facilities.
The other 20 risks
- If any of our facilities or those of our suppliers were damaged and/or our manufacturing or business processes interrupted, we could experience lost revenues and our business could be seriously harmed.
- We may have significant product liability exposure and our insurance may not cover all potential claims.
- Our private label product lines depend significantly on key relationships with third parties, which we could be unable to establish and maintain.
- RISKS RELATED TO OUR REGULATORY ENVIRONMENT
- We are subject to stringent domestic and foreign medical device regulations and oversight and any adverse action may adversely affect our ability to compete in the marketplace and our financial condition and business operations.
- Some of our activities may subject us to risks under federal and state laws prohibiting “kickbacks” and false or fraudulent claims.
- Our medical device products are subject to reporting requirements and recalls, even after receiving regulatory clearance, approval or certification, which could harm our reputation, business and financial results.
- The adoption of healthcare reform in the U.S. and initiatives sponsored by other governments may adversely affect our business, results of operations and/or financial condition.
- Certain of our products contain materials derived from animal sources and may become subject to additional regulation.
- We are subject to current and potential future requirements relating to protection of the environment, such as hazardous materials regulations, which may impose significant compliance or other costs on us.
- Environmental, social and corporate governance issues, including those related to climate change and sustainability, may have an adverse effect on our business, financial condition and results of operations and damage our reputation.
- If we do not retain our key personnel and attract and retain other highly skilled employees, our business could suffer.
- RISKS RELATED TO TAX AND DEBT
- We may have additional tax liabilities.
- Changes in tax laws or exposures to additional tax liabilities could negatively impact the Company’s operating results.
- Our leverage and debt service obligations could adversely affect our business.
- RISKS RELATED TO OUR INTELLECTUAL PROPERTY
- Our intellectual property rights may not provide meaningful commercial protection for our products, potentially enabling third parties to use our technology or very similar technology and could reduce our ability to compete in the market.
- Our competitive position depends, in part, upon unpatented trade secrets, which we may be unable to protect.
- Our success will depend partly on our ability to operate without infringing or misappropriating the proprietary rights of others.
- We may be involved in lawsuits relating to our intellectual property rights and promotional practices, which may be expensive.
- RISKS RELATED TO CYBERSECURITY AND DATA PRIVACY
- Cybersecurity incidents or other disruptions to our information technology systems could adversely affect our business.
- Failure to comply with laws relating to the confidentiality of sensitive personal information or standards related to the transmission of electronic health data, including in international jurisdictions, may require us to make significant changes to our products, or incur penalties or other liabilities.
Legal proceedings
Please refer to Note 15. Commitments and Contingencies, to the Notes to Consolidated Financial Statements (Part IV, Item 15 of this Annual Report on Form 10-K).
The opening of Item 3, Legal Proceedings.4
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14SEC EDGARMojdeh Poul, Chief executive officer
- 15
- 16
- 17
- 18SEC EDGARStuart Essig, Chair
- 19SEC EDGARPeter Arduini, President
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47SEC EDGARJeffrey A. Graves, Board member
- 48SEC EDGARRenee Wonlai Lo, Board member
- 49SEC EDGARShaundra Clay, Board member
- 50
- 51SEC EDGARLloyd Howell Jr., Board member
- 52SEC EDGARBarbara B. Hill, Board member
- 53SEC EDGARDonald E. Morel Jr., Board member
- 54SEC EDGARThomas Baltimore, Board member
- 55SEC EDGARKeith Bradley, Board member
- 56SEC EDGARJames M. Sullivan, Board member
- 57SEC EDGARRichard E. Caruso, Board member
- 58SEC EDGARAnne Vanlent, Board member
- 59SEC EDGARChristian S. Schade, Board member
- 60SEC EDGARNeal Moszkowski, Board member
- 61
- 62SEC EDGARLesha R. Shinn, General counsel
- 63SEC EDGARRegulation FD disclosure
- 64
- 65SEC EDGARRegulation FD disclosure
- 66SEC EDGARResults of operations
- 67
- 68SEC EDGARResults of operations
- 69SEC EDGARExecutive or director change
- 70SEC EDGAREntered a material agreement
- 71SEC EDGARResults of operations
- 72SEC EDGARExecutive or director change
- 73SEC EDGARResults of operations
- 74SEC EDGARResults of operations
- 75NasdaqNasdaq calendar
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91